Sign In
Buy GSK
$51.53
+0.0200 (+0.0388%)
At Close: Aug 04, 2026
GSK (GSK) is a Top-Ranked Value Stock: Should You Buy?
10:46am, Monday, 23'rd Jun 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
GSK Stock Rises Almost 22% in 6 Months: Time to Buy, Sell or Hold?
11:25am, Wednesday, 18'th Jun 2025
GSK stock is up 21.5% in six months, fueled by strong Specialty Medicines growth and a promising pipeline despite vaccine headwinds.
AstraZeneca and GSK fall after Trump renews pharma tariff threat
09:48am, Wednesday, 18'th Jun 2025
Shares in AstraZeneca PLC (LSE:AZN), the largest company on the FTSE 100 index, and fellow blue chip GSK PLC (LSE:GSK, NYSE:GSK) were down 1.4% and 1.9% respectively on renewed worries about US dru
Here's Why GSK (GSK) is a Strong Momentum Stock
10:50am, Tuesday, 17'th Jun 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
EMA Accepts GSK's Filing for Expanded Use of RSV Vaccine Arexvy
12:20pm, Monday, 16'th Jun 2025
GSK's regulatory filing for expanded use of RSV vaccine, Arexvy, in adults aged 18 years and older has been accepted for review by the EMA.
GSK announces the Linked by Lupus: Optimal Care Initiative to help support individuals with lupus in the US
09:33am, Monday, 16'th Jun 2025
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced the launch of the Linked by Lupus: Optimal Care Initiative to help support individuals impacted with lupus, particularly systemic
GSK seeks broader European approval for RSV vaccine
05:01am, Friday, 13'th Jun 2025
GSK PLC (LSE:GSK, NYSE:GSK) has taken a step towards widening access to its respiratory syncytial virus (RSV) vaccine in Europe, with the European Medicines Agency accepting its application to expand
GSK says EU heath regulator reviewing expansion of RSV vaccine
02:14am, Friday, 13'th Jun 2025
GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its respiratory syncytial virus vaccine, Arexvy, to include adults from 18 years of age.
Vaccine Stocks Moderna, Pfizer Hit After A Surprise Blow From RFK Jr.
06:07pm, Monday, 09'th Jun 2025
Vaccines stocks slipped late Monday after HHS fired all members of a CDC committee in charge of making vaccine suggestions.
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
09:19am, Monday, 09'th Jun 2025
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high
Here's Why GSK (GSK) is a Strong Value Stock
10:41am, Friday, 06'th Jun 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
FDA Accepts GSK's NDA for Linerixibat in Rare Disease-Related Itch
12:46pm, Tuesday, 03'rd Jun 2025
GSK's NDA for linerixibat, for treating itch in PBC patients, gets FDA review with a decision due in March 2026.
Dow Jones Industrial Average (DIA) Live June 3: OECD Cuts US GDP Forecast, DIA Dives
09:34am, Tuesday, 03'rd Jun 2025
The OECD lowered US GDP forecasts for 2025 and 2026 today. Meta and Constellation are teaming up in a nuclear power supply agreement that will last 20 years.
Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million
06:00am, Monday, 02'nd Jun 2025
Definitive agreement to result in one-time $225 million cash payment Theravance Biopharma retains rights to up to $150 million in milestones from Royalty Pharma on Trelegy Ellipta net sales in 202
Glaxo (GSK) Up 3.2% Since Last Earnings Report: Can It Continue?
12:36pm, Friday, 30'th May 2025
Glaxo (GSK) reported earnings 30 days ago. What's next for the stock?
